CymaBay Therapeutics, Inc. (0I5P.L) LSE
32.48
+0.0029(+0.01%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
CymaBay Therapeutics, Inc.
Address
7575 Gateway Boulevard
Newark, CA 94560
United States of America (the)
Phone
510 293 8800
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
101
First IPO Date
January 29, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Sujal A. Shah | President, Chief Executive Officer & Director | 1.04M | 1973 |
| Klara A. Dickinson-Eason | Chief Regulatory & Quality Assurance Officer | 441,836 | 1968 |
| Paul T. Quinlan | General Counsel, Chief Compliance Officer & Corporate Secretary | 629,720 | 1963 |
| Charles A. McWherter | President of Research & Development and Chief Scientific Officer | 700,648 | 1955 |
| Robert L. Martin | Senior Vice President of Manufacturing & Nonclinical Development | 0 | 1962 |
| Ben Kozub | Head of Commercial | 0 | N/A |
| Harish Shantharam | Chief Financial Officer, Principal Accounting & Financial Officer | 0 | 1982 |
| Ken Boehm | Senior Vice President of Human Resources | 0 | N/A |
| Patrick J. O'Mara | Senior Vice President of Business Development | 0 | 1961 |
| Becki Filice | 130494Senior Vice President of Portfolio & Product Leadership | 0 | 1961 |
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
